• Agreement brings expanded Biologics to in-vitro Diagnostics Industry
    Urs Spitz (left) and Jan Modregger
  • Urs Spitz and Jan Modregger

News & Views

Agreement brings expanded Biologics to in-vitro Diagnostics Industry

Aug 08 2022

EUCODIS Bioscience, specialists in engineering and developing enzymes for pharma, biotech and applied markets has been acquired by Biosynth Carbosynth, a supplier of critical biological materials to the life science industry.  Having already worked together for a number of years, the agreement broadens Biosynth’s biological products and its custom services offerings in enzymes and chemical syntheses, to enable novel biocatalytic synthesis routes for small molecules.

The expanded range of enzymes, antibodies, antigens, plasma along with epitope mapping , complements  the biological materials supplied by Biosynth via its Aalto Bio Reagents subsidiary. As part of the Biosynth group, EUCODIS will continue to provide state of the art services with the added benefit that customers will now profit from the combined expertise of EUCODIS and Biosynth.

Dr. Urs Spitz, CEO and President of Biosynth, said, “Biosynth has collaborated with EUCODIS for many years, working on innovative enzyme projects for our customers and perfectly complementing our extensive expertise in enzyme substrate chemistry.  It makes absolute sense for EUCODIS to join us as a key part of our biological materials offering. We are delighted to be able to welcome the experienced and knowledgeable team we know so well into the Biosynth family.”

Dr. Jan Modregger, CEO of EUCODIS, added, “We are pleased to be joining Biosynth, a group with which we have enjoyed a longstanding relationship and which shares our science-led and customer focused philosophy. We are excited by the opportunity to grow even faster and to provide high performance enzymes and biocatalysis solutions to a global customer base.”

More information online

Digital Edition

Lab Asia 29.6 Dec

December 2022

In This Edition Chromatography - Optimising Viral Vector Purification Strategies with Multimodal Chromatography - Key UHPLC Characteristics Required for High throughput LC-MS - New Low Volu...

View all digital editions


Arab Health

Jan 30 2023 Dubai, UAE

Nano Tech 2023

Feb 01 2023 Tokyo, Japan

Medlab Middle East

Feb 06 2023 Dubai, UAE


Feb 14 2023 Cologne, Germany

View all events